253 related articles for article (PubMed ID: 31050100)
1. The factor VIII:C/VWF:Ag ratio as a useful tool to predict relapse in patients with acquired haemophilia A: A retrospective cohort study.
Trossaert M; Graveleau J; Thiercelin-Legrand MF; Sigaud M; Guerrero F; Neel A; Fouassier M; Sailler L; Chauveau D; Ternisien C; Huart A; Gillet B; Hamidou M; Bene MC; Voisin S
Haemophilia; 2019 May; 25(3):527-534. PubMed ID: 31050100
[TBL] [Abstract][Full Text] [Related]
2. Relapse pattern and long-term outcomes in subjects with acquired haemophilia A.
Mizrahi T; Doyon K; Dubé E; Bonnefoy A; Warner M; Cloutier S; Demers C; Castilloux JF; Rivard GE; St-Louis J
Haemophilia; 2019 Mar; 25(2):252-257. PubMed ID: 30694571
[TBL] [Abstract][Full Text] [Related]
3. Relapse of Acquired Hemophilia A after COVID-19 Infection.
Marumo A; Sugihara H; Omori I; Morishita E
J Nippon Med Sch; 2024 Jan; 90(6):474-479. PubMed ID: 36823120
[TBL] [Abstract][Full Text] [Related]
4. DDAVP infusion in haemophilia A carriers: different behaviour of plasma factor VIII and von Willebrand factor.
Casonato A; Dannhauser D; Pontara E; Bertomoro A; Orazi B; Santarossa L; Zerbinati P; Girolami A
Blood Coagul Fibrinolysis; 1996 Jul; 7(5):549-53. PubMed ID: 8874865
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis of von Willebrand disease type 2N: a simplified method for measurement of factor VIII binding to von Willebrand factor.
Miller CH; Kelley L; Green D
Am J Hematol; 1998 Aug; 58(4):311-8. PubMed ID: 9692396
[TBL] [Abstract][Full Text] [Related]
6. Does the presence of von Willebrand factor in FVIII-deficient plasma influences the measurement of FVIII inhibitor titres in haemophilia A patients?
Pouplard C; Desconclois C; Sobas F; Aillaud MF; Ternisien C; Caron C
Int J Lab Hematol; 2015 Feb; 37(1):125-32. PubMed ID: 24815078
[TBL] [Abstract][Full Text] [Related]
7. Further evidence for recessive inheritance of von Willebrand disease with abnormal binding of von Willebrand factor to factor VIII.
López-Fernández MF; Blanco-López MJ; Castiñeira MP; Batlle J
Am J Hematol; 1992 May; 40(1):20-7. PubMed ID: 1566742
[TBL] [Abstract][Full Text] [Related]
8. Standardisation of factor VIII and von Willebrand factor in plasma: calibration of the 4th International Standard (97/586).
Hubbard AR; Rigsby P; Barrowcliffe TW
Thromb Haemost; 2001 Apr; 85(4):634-8. PubMed ID: 11341497
[TBL] [Abstract][Full Text] [Related]
9. Relationships between factor VIII:Ag and factor VIII in recombinant and plasma-derived factor VIII concentrates.
Lin Y; Yang X; Chevrier MC; Craven S; Barrowcliffe TW; Lemieux R; Ofosu FA
Haemophilia; 2004 Sep; 10(5):459-69. PubMed ID: 15357771
[TBL] [Abstract][Full Text] [Related]
10. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
[TBL] [Abstract][Full Text] [Related]
11. Identifying risk factors and optimizing standard of care for patients with acquired haemophilia A: Results from a Czech patient cohort.
Salaj P; Geierová V; Ivanová E; Loužil J; Pohlreichová V; Hrachovinová I; Dulíček P
Haemophilia; 2020 Jul; 26(4):643-651. PubMed ID: 32590889
[TBL] [Abstract][Full Text] [Related]
12. Evidence for a von Willebrand factor defect in factor VIII binding in three members of a family previously misdiagnosed mild haemophilia A and haemophilia A carriers: consequences for therapy and genetic counselling.
Mazurier C; Gaucher C; Jorieux S; Parquet-Gernez A; Goudemand M
Br J Haematol; 1990 Nov; 76(3):372-9. PubMed ID: 2124499
[TBL] [Abstract][Full Text] [Related]
13. Different factor VIII neutralizing effects on anti-factor VIII inhibitor antibodies associated with epitope specificity and von Willebrand factor.
Yada K; Nogami K; Shima M
Br J Haematol; 2013 Oct; 163(1):104-11. PubMed ID: 23889549
[TBL] [Abstract][Full Text] [Related]
14. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).
Michiels JJ; Berneman ZN; van der Planken M; Schroyens W; Budde U; van Vliet HH
Blood Coagul Fibrinolysis; 2004 Jun; 15(4):323-30. PubMed ID: 15166918
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic and prognostic value of factor VIII binding antibodies in acquired hemophilia A: data from the GTH-AH 01/2010 study.
Werwitzke S; Geisen U; Nowak-Göttl U; Eichler H; Stephan B; Scholz U; Holstein K; Klamroth R; Knöbl P; Huth-Kühne A; Bomke B; Tiede A
J Thromb Haemost; 2016 May; 14(5):940-7. PubMed ID: 26988717
[TBL] [Abstract][Full Text] [Related]
16. Validation of the first commercial ELISA for type 2N von Willebrand's disease diagnosis.
Veyradier A; Caron C; Ternisien C; Wolf M; Trossaert M; Fressinaud E; Goudemand J
Haemophilia; 2011 Nov; 17(6):944-51. PubMed ID: 21371195
[TBL] [Abstract][Full Text] [Related]
17. First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study.
Kreuz W; Escuriola Ettingshausen C; Vdovin V; Zozulya N; Plyushch O; Svirin P; Andreeva T; Bubanská E; Campos M; Benedik-Dolničar M; Jiménez-Yuste V; Kitanovski L; Klukowska A; Momot A; Osmulskaya N; Prieto M; Šalek SZ; Velasco F; Pavlova A; Oldenburg J; Knaub S; Jansen M; Belyanskaya L; Walter O; ;
Haemophilia; 2016 Jan; 22(1):87-95. PubMed ID: 26202305
[TBL] [Abstract][Full Text] [Related]
18. Anti-factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 study.
Tiede A; Hofbauer CJ; Werwitzke S; Knöbl P; Gottstein S; Scharf RE; Heinz J; Groß J; Holstein K; Dobbelstein C; Scheiflinger F; Koch A; Reipert BM
Blood; 2016 May; 127(19):2289-97. PubMed ID: 26912467
[TBL] [Abstract][Full Text] [Related]
19. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
[TBL] [Abstract][Full Text] [Related]
20. Effects of moderate-intensity physical exercise on pharmacokinetics of factor VIII and von Willebrand factor in young adults with severe haemophilia A: a pilot study.
Zourikian N; Merlen C; Bonnefoy A; St-Louis J; Rivard GE
Haemophilia; 2016 May; 22(3):e177-83. PubMed ID: 26988074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
